CY1112391T1 - Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων - Google Patents

Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων

Info

Publication number
CY1112391T1
CY1112391T1 CY20121100185T CY121100185T CY1112391T1 CY 1112391 T1 CY1112391 T1 CY 1112391T1 CY 20121100185 T CY20121100185 T CY 20121100185T CY 121100185 T CY121100185 T CY 121100185T CY 1112391 T1 CY1112391 T1 CY 1112391T1
Authority
CY
Cyprus
Prior art keywords
phenyl
substituted
dipyrrolidine
urine
therapeutic uses
Prior art date
Application number
CY20121100185T
Other languages
Greek (el)
English (en)
Inventor
Werngard Czechtizky
Zhongli Gao
William J Hurst
Lothar Schwink
Siegfried Stengelin
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of CY1112391T1 publication Critical patent/CY1112391T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CY20121100185T 2007-10-17 2012-02-23 Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων CY1112391T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98060607P 2007-10-17 2007-10-17
EP08838702A EP2215058B1 (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof

Publications (1)

Publication Number Publication Date
CY1112391T1 true CY1112391T1 (el) 2015-12-09

Family

ID=40248052

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100185T CY1112391T1 (el) 2007-10-17 2012-02-23 Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων

Country Status (24)

Country Link
US (1) US8222290B2 (OSRAM)
EP (1) EP2215058B1 (OSRAM)
JP (1) JP5380455B2 (OSRAM)
KR (1) KR20100082349A (OSRAM)
CN (1) CN101903341B (OSRAM)
AT (1) ATE534625T1 (OSRAM)
AU (1) AU2008312641A1 (OSRAM)
CA (1) CA2702933C (OSRAM)
CY (1) CY1112391T1 (OSRAM)
DK (1) DK2215058T3 (OSRAM)
ES (1) ES2378011T3 (OSRAM)
HR (1) HRP20120166T1 (OSRAM)
IL (1) IL205002A0 (OSRAM)
MA (1) MA31889B1 (OSRAM)
MX (1) MX2010003948A (OSRAM)
MY (1) MY148807A (OSRAM)
NZ (1) NZ584692A (OSRAM)
PL (1) PL2215058T3 (OSRAM)
PT (1) PT2215058E (OSRAM)
RS (1) RS52221B (OSRAM)
RU (1) RU2478094C2 (OSRAM)
SI (1) SI2215058T1 (OSRAM)
WO (1) WO2009052068A1 (OSRAM)
ZA (1) ZA201002114B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5377504B2 (ja) 2007-10-17 2013-12-25 サノフイ 置換されたｎ−フェニル−ピロリジニルメチルピロリジンアミドおよびその治療的用途
RU2477720C2 (ru) * 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях
HRP20110953T1 (hr) 2007-10-17 2012-01-31 Sanofi Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji
KR20090129927A (ko) 2008-06-13 2009-12-17 주식회사 엘지화학 발열체 및 이의 제조방법
US10412788B2 (en) 2008-06-13 2019-09-10 Lg Chem, Ltd. Heating element and manufacturing method thereof
WO2009151203A1 (ko) * 2008-06-13 2009-12-17 주식회사 엘지화학 발열체 및 이의 제조방법
WO2011143148A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
TW201206910A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
JP5784110B2 (ja) 2010-05-11 2015-09-24 サノフイ 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用
JP5766278B2 (ja) 2010-05-11 2015-08-19 サノフイ 置換されたｎ−アルキルおよびｎ−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用
WO2011143163A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
TW201206901A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
AR083855A1 (es) * 2010-11-15 2013-03-27 Abbott Lab Inhibidores de nampt y rock
BR112013021496B1 (pt) * 2011-02-23 2021-10-13 Suven Life Sciences Limited Composto, composição farmacêutica, uso da composição farmacêutica, processo para a preparação de um composto e uso do composto

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
JP2006505590A (ja) * 2002-10-23 2006-02-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体調節物質としてのフェニルピペリジンおよびフェニルピロリジン
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
CA2600757C (en) 2005-03-17 2014-02-18 Eli Lilly And Company Pyrrolidine derivatives as histamine h3 receptor antagonists
EP1868991B1 (en) * 2005-04-01 2014-07-30 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
CA2613192C (en) * 2005-07-01 2013-12-31 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
TW200804274A (en) * 2005-10-27 2008-01-16 Ucb Sa Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
JP5377504B2 (ja) 2007-10-17 2013-12-25 サノフイ 置換されたｎ−フェニル−ピロリジニルメチルピロリジンアミドおよびその治療的用途
RU2477720C2 (ru) 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях
HRP20110953T1 (hr) 2007-10-17 2012-01-31 Sanofi Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji

Also Published As

Publication number Publication date
CA2702933C (en) 2012-12-18
MX2010003948A (es) 2010-04-30
KR20100082349A (ko) 2010-07-16
ES2378011T3 (es) 2012-04-04
CN101903341B (zh) 2012-10-03
RU2010119554A (ru) 2011-11-27
US20100173908A1 (en) 2010-07-08
HRP20120166T1 (hr) 2012-03-31
US8222290B2 (en) 2012-07-17
ATE534625T1 (de) 2011-12-15
PT2215058E (pt) 2012-03-06
ZA201002114B (en) 2010-12-29
NZ584692A (en) 2011-12-22
EP2215058B1 (en) 2011-11-23
JP2011500697A (ja) 2011-01-06
MY148807A (en) 2013-05-31
AU2008312641A1 (en) 2009-04-23
PL2215058T3 (pl) 2012-04-30
EP2215058A1 (en) 2010-08-11
MA31889B1 (fr) 2010-12-01
HK1146056A1 (en) 2011-05-13
DK2215058T3 (da) 2012-03-12
WO2009052068A1 (en) 2009-04-23
RS52221B (sr) 2012-10-31
CA2702933A1 (en) 2009-04-23
CN101903341A (zh) 2010-12-01
SI2215058T1 (sl) 2012-03-30
IL205002A0 (en) 2010-11-30
RU2478094C2 (ru) 2013-03-27
JP5380455B2 (ja) 2014-01-08

Similar Documents

Publication Publication Date Title
CY1112391T1 (el) Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων
CY1112083T1 (el) Υποκαθιστουμενα ν-φαινυλο-διπυρρολιδινο καρβοξαμιδια και η θεραπευτικη τους χρηση
CY1112683T1 (el) Υποκατεστημενες καρβοξαμιδες ν-φαινυλ-διπυρρολιδινης και θεραπευτικες χρησεις τους
MY150210A (en) Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
MA29136B1 (fr) Agents de potentialisation de recepteurs du glutamate
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
UA104880C2 (uk) Заміщені тетрагідропіранспіропіролідинон і тетрагідропіранспіропіперидинон, спосіб їх одержання й застосування в лікувальних цілях
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
ATE502947T1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren